NEUROLOGIX'S GENE THERAPY PRECLINICAL RESULTS REPORTED
Neurologix has announced results from preclinical studies, which showed that Neuropeptide Y (NPY) gene transfer reduces spontaneous seizures in an in vivo model of epilepsy as well as positively influences the fundamental biological process that leads to a chronically epileptic state. Neurologix's approach is based on the use of the non-pathogenic adeno-associated virus (AAV) vector, delivered using standard neurosurgical techniques. NPY, a 36-amino acid peptide that acts to dampen excessive excitatory activity, prevents seizures in multiple models.
Previous research has shown that the gene therapy candidate had robust anti-epileptic activity in acute seizure animal models with efficacy exceeding that of traditional small molecule anti-epileptic drugs.